← Back to Search

Non-Pharmacological Therapy

TMS for Autism

N/A
Recruiting
Led By James McPartland, PhD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Individuals between the ages of 18 and 40 years old with typical development or with a diagnosis of autism spectrum disorder
Be between 18 and 65 years old
Must not have
Females of known/suspected pregnancy or who test positive on a pregnancy test
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measures will be recorded during the eeg/et sessions of participant visits for an expected 1-2 hours

Summary

This trial will study whether a brain stimulation treatment can improve social cognition in adults with ASD.

Who is the study for?
This trial is for adults aged 18-40 with autism spectrum disorder (ASD) or typical development, able to undergo EEG and eye-tracking tests. It excludes those with major psychiatric illnesses, pregnant women, individuals with an IQ below 80, history of seizures or serious medical conditions, recent drug/alcohol use, prior TMS therapy or investigational drug use within the last 12 weeks.
What is being tested?
The study is testing repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain. The goal is to see how rTMS affects social cognition in adults with ASD.
What are the potential side effects?
Possible side effects of rTMS include discomfort at the stimulation site, headache, lightheadedness, tingling or spasms in facial muscles. Rarely it can cause seizures or hearing loss if ear protection isn't used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 40 years old, with or without autism.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not pregnant nor suspect I might be.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measures will be recorded during the eeg/et sessions of participant visits for an expected 1-2 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and measures will be recorded during the eeg/et sessions of participant visits for an expected 1-2 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
proportion of visual attention to the eye region of the face
right hemisphere N170 latency

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Transcranial Magnetic Stimulation - realActive Control1 Intervention
Participants will receive active TMS during their study visit
Group II: Transcranial Magnetic Stimulation - shamPlacebo Group1 Intervention
Participants will receive sham stimulation during their study visit simulating TMS

Find a Location

Who is running the clinical trial?

United States Department of DefenseFED
916 Previous Clinical Trials
334,657 Total Patients Enrolled
18 Trials studying Autism Spectrum Disorder
1,700 Patients Enrolled for Autism Spectrum Disorder
Yale UniversityLead Sponsor
1,930 Previous Clinical Trials
3,033,160 Total Patients Enrolled
27 Trials studying Autism Spectrum Disorder
2,377 Patients Enrolled for Autism Spectrum Disorder
James McPartland, PhDPrincipal InvestigatorYale University
5 Previous Clinical Trials
1,291 Total Patients Enrolled
5 Trials studying Autism Spectrum Disorder
1,291 Patients Enrolled for Autism Spectrum Disorder

Media Library

Transcranial Magnetic Stimulation (TMS) (Non-Pharmacological Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04936009 — N/A
Autism Spectrum Disorder Research Study Groups: Transcranial Magnetic Stimulation - sham, Transcranial Magnetic Stimulation - real
Autism Spectrum Disorder Clinical Trial 2023: Transcranial Magnetic Stimulation (TMS) Highlights & Side Effects. Trial Name: NCT04936009 — N/A
Transcranial Magnetic Stimulation (TMS) (Non-Pharmacological Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04936009 — N/A
~0 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top